An interventional study of glUCModel app in Diabetes (Insulin-requiring, Type 1 or Type 2), sponsored by Universidad Complutense de Madrid. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Universidad Complutense de Madrid · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 254 studies in Diabetes Mellitus with a site in Spain — 20 open to participants now, 29 under way, 5 of them phase 3. Diabetes Mellitus · Spain.
Among the 254 studies in Diabetes Mellitus with a site in Spain, this one is the 194th largest by planned enrollment of the 211 interventional ones that give a count, is one of 10 that started in 2025, is one of 65 with no phase, reaches primary completion later than 11 of the 28 other live ones, and was the 245th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →20 of the 254 studies in Diabetes Mellitus with a site in Spain are open now. Recruiting first, the newest first:
Eduardo Luis Martín Javier · Sites in Spain
Ages 18+
Pfizer · Sites in Spain, United States, Brazil and 8 more countries
Ages 18+
Consorci Sanitari de l'Alt Penedès i Garraf · Sites in Spain
Ages 18+
Instituto de Ciencia y Tecnología de Alimentos y Nutrición · Sites in Spain
Ages 20–70
Persei Vivarium · Sites in Spain
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
254 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 24 · Phase 3 97 · Phase 4 27
First in 1994; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34 is below the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 394 across the 211 interventional studies, 512 across the 42 observational. Of the 193 that completed or were terminated, 89 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
145 of 254 have an industry lead sponsor. The 10 most frequent:
Universidad Complutense de Madrid is the lead sponsor of 206 studies on the registry; 63 are open to participants now.
Universidad Complutense de Madrid has 7 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
6 of the studies in Diabetes Mellitus with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05769868Phase 3Consorcio Centro de Investigación Biomédica en Red (CIBER)Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments | 2027-03 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT05243368Maimónides Biomedical Research Institute of CórdobaEvaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics | 2026-12-30 |
| NCT07463456Eduardo Luis Martín JavierInter-Device Concordance of Plantar Thermal Asymmetry Measurement (HIK-DM-2026) | 2027-04 |
| NCT07285330Consorci Sanitari de l'Alt Penedès i GarrafDietitian-Nutritionist vs. Day Hospital in the Metabolic Control of Patients With Type 2 Diabetes | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 254 studies in Diabetes Mellitus with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the safety and efficacy of integrating predictive models into insulin therapy management via the user-centered glUCModel mobile app in People with Type 1 Diabetes Mellitus following Multiple Insulin Dosing therapy. Participants will be aged 18 to 65 years. The main questions it aims to answer are:
Does using the app improve glycaemic control, as measured by time in range? Does using the app reduce the number of episodes of hyperglycaemia and hypoglycaemia? Are the app's design and functionality adequate?
The study will comprise four phases:ses}):
Diabetes mellitus is a chronic, metabolic disorder characterized by impaired regulation of blood glucose, affecting more than 400 million people worldwide. Insulin, a hormone produced by the pancreas, facilitates the uptake of glucose into cells for energy production. In diabetes, either insufficient insulin is produced or the body cannot use it effectively, leading to persistent hyperglycemia. Over time, uncontrolled glucose levels can result in serious complications, including cardiovascular disease, neuropathy, retinopathy, and nephropathy. Effective management is therefore essential to prevent both acute and long-term adverse outcomes.
Two main forms of diabetes can be distinguished. Type 1 diabetes mellitus (T1DM) is an autoimmune condition in which pancreatic β-cells are destroyed, resulting in absolute insulin deficiency. It accounts for approximately 10% of all cases. Individuals with T1DM require lifelong insulin replacement therapy, typically delivered as multiple daily injections (MDI) or via an insulin pump. In contrast, type 2 diabetes mellitus (T2DM), the more prevalent form, is characterized primarily by insulin resistance. While insulin production is preserved in early stages, progressive dysfunction may ultimately necessitate pharmacological therapy, including insulin. Lifestyle interventions such as healthy diet and physical activity can delay or prevent T2DM onset and progression.
For individuals with diabetes, day-to-day self-management requires frequent glucose monitoring and insulin dose adjustments that must take into account meals, physical activity, stress, illness, and other factors. Capillary glucose meters and, more recently, continuous glucose monitoring systems (CGMs) have greatly improved access to real-time glucose data. However, interpreting these data and deciding on corrective actions remains challenging, and errors in insulin dosing can lead to hypoglycemia or persistent hyperglycemia. Both acute complications and the constant decision-making load contribute to reduced quality of life and treatment fatigue.
To support patients in these complex tasks, predictive models of glucose dynamics have been extensively investigated. Accurate prediction could enable early warnings of hypo- or hyperglycemia and assist in optimizing insulin therapy. The ultimate vision is the development of a fully automated ''artificial pancreas'' combining glucose sensing, insulin delivery, and robust prediction algorithms. Various machine learning (ML) approaches have been explored for glucose forecasting, including Genetic Programming , K-Nearest Neighbours , Grammatical Evolution, and, most prominently, Neural Networks. Among neural architectures, Long Short-Term Memory (LSTM) and other recurrent models have demonstrated strong performance for time-series data such as CGM traces, although convolutional and multilayer perceptron (MLP) networks have also been applied. Despite encouraging results, challenges remain in ensuring accuracy, robustness, and real-world usability across diverse patient populations.
Managing T1DM, particularly in patients using MDI, continues to pose a major challenge. While CGM and insulin pumps have improved outcomes, decisions about insulin dosing still depend heavily on patient intuition and experience, leaving room for error and variability. There is therefore a clear need for decision-support tools that combine predictive analytics with personalized recommendations to enhance safety, autonomy, and treatment adherence.
The glUCModel mobile application was developed to address this need. Since its early versions, it integrates proprietary, patented artificial intelligence models to provide real-time insulin recommendations, short-term glucose forecasts, and predictive alerts for hypo- and hyperglycemia. With a forecast horizon of up to two hours, the system aims to reduce glycemic variability and support timely corrective actions.
This protocol describes a randomized, open-label clinical study to evaluate the efficacy and safety of the glUCModel application in patients with T1DM using MDI therapy. The primary objective is to assess improvement in short-term glycemic control, measured by the percentage of time spent in target range (70-180 mg/dL). Secondary objectives include reductions in glycemic excursions, improved treatment satisfaction, and evaluation of usability and adherence in a real-world setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Currently following an MDI Bolus-Basal therapy.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants continue MDI therapy. The intervention group will additionally use the glUCModel app. CGM data from the final 2 weeks will be analyzed
Other: glUCModel app
Participants continue MDI therapy. CGM data from the final 2 weeks will be analyzed
The intervention consists on using glUCModel, an application designed to help people with diabetes. It features a suite of artificial intelligence tools and statistical techniques for capturing and managing key information that people with diabetes need to track, as well as for predicting glucose values to aid users in informed decision-making.
Time in Range (TIR)
Time in Range (TIR), defined as the percentage of time that interstitial glucose is between 70-180 mg/dL during the final 2 weeks of the intervention phase
Time frame: During the last 2 weeks of intervention
Usability and adherence
Patient-reported outcomes on usability and adherence through uMARS. The usability of the app will be evaluated using the Spanish Version of the User Version of the Mobile Application Rating Scale (uMARS). This scale provides a comprehensive and objective measure of app usability and consists of 20 items. Each item is rated on a 5-point scale, ranging from 1 (inadequate) to 5 (excellent).
Time frame: Two weeks
Frequency of Level 1 hypoglycemia
Frequency in minutes of Level 1 hypoglycemia (40 ≤ CGM glucose \< 55).
Time frame: During the last 2 weeks of intervention
Frequency of Level 2 hypoglycemias
Frequency in minutes of Level 2 hypoglycemia (55 ≤ interstitial glucose ≤ 70)
Time frame: During the last 2 weeks of intervention
Frequency of Level 1 hyperglycemias
Frequency in minutes of Level 1 hyperglycemia (180 ≤ CGM glucose ≤ 240).
Time frame: During the last 2 weeks of intervention
Frequency of Level 2 hyperglycemias
Frequency in minutes of Level 2 hyperglycemia (241 ≤ interstitial glucose ≤ 400).
Time frame: During the last 2 weeks of the intervention
Duration of Level 1 hypoglycemias
Average Duration in minutes of Level 1 hypoglycemia (40 ≤ CGM glucose \< 55)
Time frame: During the last 2 weeks of intervention
Duration of Level 2 hypoglycemia
Average duration in minutes of Level 2 hypoglycemia (55 ≤ interstitial glucose ≤ 70).
Time frame: During the last 2 weeks of intervention
Duration of Level 1 hyperglycemias
Average duration in minutes of Level 1 hyperglycemia (180 ≤ CGM glucose ≤ 240).
Time frame: During the last 2 weeks of intervention
Duration of Level 2 hyperglycemias
Average duration in minutes of Level 2 hyperglycemia (241 ≤ interstitial glucose ≤ 400).
Time frame: During the last 2 weeks of the intervention
Glycemic coefficient of variation
Coefficient of Variation (CV) is calculated using the mean and the standard deviation of the glucose values. Coefficient of Variation (CV) is calculated by dividing the Standard Deviation by the mean of the glucose values.
Time frame: During the last 2 weeks of intervention
Glycemic variability
Glycemic variability is computed as the standard deviation. Standard Deviation (SD) is measured as the dispersion of glucose values from the average.
Time frame: During the last 2 weeks of intervention
Accepted Recommendations
Percentage of insulin recommendations accepted and applied by the user from the total number of recommendations requested.
Time frame: During the last 2 weeks of intervention
Quality of predictions
Quality of predictions measured using the Parkes Errod Grid analysis.
Time frame: During the last 2 weeks of intervention
Treatment satisfaction
Treatment satisfaction using the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Time frame: last 2 weeks of the intervention
Sleep Quality before the intervention
We will evaluate Sleep Quality before and after the intervention. The Pittsburg Sleep Quality Index (PSQI) will be used. The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties. https://www.sleep.pitt.edu/psqi
Time frame: The day of the start of the intervention
Sleep Quality after the intervention
We will evaluate Sleep Quality before and after the intervention. The Pittsburg Sleep Quality Index (PSQI) will be used. The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties. https://www.sleep.pitt.edu/psqi
Time frame: Two weeks after the day of the end of the intervention
Plan to share: Undecided — It depends on the autorization of the University
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Feb 2026, 6 months after the start.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 6 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad Complutense de Madrid →